Terug
59
27
Ook genoteerd als
OPHLY
OTC
Dagbereik
€ 14,00
€ 16,00
52-Weeksbereik
€ 9,20
€ 18,67
Volume
625
50D / 200D Gem.
€ 15,37
/
€ 12,48
Vorige Slotkoers
€ 14,00
Koershistorie
Financiële Trends
Sectorvergelijking
vs Healthcare sector mediaan (627 peers)
| Metriek | Aandeel | Sector Mediaan |
|---|---|---|
| P/E | 0,1 | 0,3 |
| P/B | 0,0 | 2,9 |
| ROE % | 6,4 | 3,7 |
| Net Margin % | 10,3 | 3,8 |
| Rev Growth 5Y % | 12,0 | 10,0 |
| D/E | 0,2 | 0,2 |
Koersdoel Analisten
Geen analistendekking beschikbaar
Winstschattingen
| Periode | WPA Sch. | Omzet Sch. | Analisten |
|---|---|---|---|
| FY2030 |
€ 133,84
€ 122,73 – € 144,81
|
470 B | 1 |
| FY2029 |
€ 130,53
€ 119,70 – € 141,24
|
470 B | 1 |
| FY2028 |
€ 120,40
€ 110,41 – € 130,27
|
450 B | 1 |
Belangrijkste Punten
Revenue grew 12,01% annually over 5 years — strong growth
Earnings declined -60,89% over the past year
Debt/Equity of 0,19 — conservative balance sheet
Generating 74,47B in free cash flow
P/E of 0,13 — trading at a low valuation
Revenue growth is decelerating — 1Y growth trails 5Y average by 15,15%
Groei
Revenue Growth (5Y)
12,01%
Revenue (1Y)-3,14%
Earnings (1Y)-60,89%
FCF Growth (3Y)-28,36%
Kwaliteit
Return on Equity
6,35%
ROIC4,82%
Net Margin10,28%
Op. Margin12,27%
Veiligheid
Debt / Equity
0,19
Current Ratio3,07
Interest Coverage11,23
Waardering
P/E Ratio
0,13
P/B Ratio0,01
EV/EBITDA-0,86
Dividend Yield0,05%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | -3,14% | Revenue Growth (3Y) | 4,34% |
| Earnings Growth (1Y) | -60,89% | Earnings Growth (3Y) | -33,37% |
| Revenue Growth (5Y) | 12,01% | Earnings Growth (5Y) | -9,75% |
| Profitability | |||
| Revenue (TTM) | 486,87B | Net Income (TTM) | 50,05B |
| ROE | 6,35% | ROA | 4,70% |
| Gross Margin | 69,61% | Operating Margin | 12,27% |
| Net Margin | 10,28% | Free Cash Flow (TTM) | 74,47B |
| ROIC | 4,82% | FCF Growth (3Y) | -28,36% |
| Safety | |||
| Debt / Equity | 0,19 | Current Ratio | 3,07 |
| Interest Coverage | 11,23 | Dividend Yield | 0,05% |
| Valuation | |||
| P/E Ratio | 0,13 | P/B Ratio | 0,01 |
| P/S Ratio | 0,01 | PEG Ratio | -0,26 |
| EV/EBITDA | -0,86 | Dividend Yield | 0,05% |
| Market Cap | 6,58B | Enterprise Value | -51,31B |
Income Statement
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 486,87B | 502,67B | 447,19B | 361,36B | 309,28B |
| Net Income | 50,05B | 127,98B | 112,72B | 80,52B | 75,43B |
| EPS (Diluted) | 106,41 | 266,60 | 230,79 | 162,16 | 151,09 |
| Gross Profit | 338,92B | 375,55B | 337,13B | 267,85B | 223,71B |
| Operating Income | 59,75B | 163,10B | 152,29B | 114,91B | 92,10B |
Balance Sheet
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 1,06T | 913,67B | 882,44B | 739,20B | 746,84B |
| Total Liabilities | 275,84B | 115,06B | 134,62B | 77,53B | 105,69B |
| Shareholders' Equity | 782,45B | 792,96B | 741,87B | 655,91B | 635,55B |
| Total Debt | 146,68B | 8,86B | 9,17B | 8,80B | 9,05B |
| Cash & Equivalents | 204,57B | 166,14B | 96,14B | 69,11B | 61,05B |
| Current Assets | 455,10B | 413,60B | 345,10B | 281,27B | 247,64B |
| Current Liabilities | 148,30B | 103,62B | 122,93B | 65,93B | 93,73B |
Strategiescores
This stock passed the criteria for 2 strategies
Score = fit strength (0–100)
Rank = position among all matches
#155 of 825
#374 of 709
Recente Activiteit
Ingestapt
Deep Value Investing (Seth Klarman)
Mar 24, 2026
Ingestapt
Defensive Investing (Benjamin Graham)
Mar 24, 2026